Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21602301 | 0.86 | LMNA (0.44) | LMNACYP2C9 | |
| SCHEMBL22216490 | 0.85 | NT5E (0.39) | SLC22A12GPR119NT5EWNT3A | |
| SCHEMBL20333387 | 0.85 | CYP17A1 (0.45) | KIF11SLC22A12GPR119NT5E | |
| SCHEMBL20333727 | 0.85 | MKNK1 (0.49) | MKNK1MKNK2KIF11CYP2A6PSMB5 | |
| SCHEMBL22216670 | 0.84 | MKNK1 (0.48) | MKNK1MKNK2KIF11CYP2A6PSMB5 | |
| SCHEMBL20347196 | 0.80 | MKNK1 (0.47) | MKNK1MKNK2KIF11CYP2A6PSMB5 | |
| SCHEMBL24983268 | 0.79 | FDPS (0.41) | GPR119CYP19A1 | |
| SCHEMBL24835816 | 0.78 | RARB (0.46) | — | |
| SCHEMBL22216672 | 0.78 | MME (0.41) | NT5E | |
| SCHEMBL22216282 | 0.78 | NT5E (0.43) | LMNANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | MKNK1 4515/4885MKNK2 4565/4885KIF11 4615/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | MKNK1 4515/4885MKNK2 4565/4885KIF11 4615/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | MKNK1 4515/4885MKNK2 4565/4885KIF11 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.